Literature DB >> 30617121

Development of a Universal Influenza Vaccine.

Leonardo D Estrada1, Stacey Schultz-Cherry2.   

Abstract

The severity of the 2017-18 influenza season, combined with the low efficacy for some vaccine components, highlights the need to improve our current seasonal influenza vaccine. Thus, the National Institute of Allergy and Infectious Diseases recently announced a strategic plan to improve current influenza vaccines and eventually develop a "universal" influenza vaccine. This review will highlight the many different strategies being undertaken in pursuit of this goal and the exciting advances made by the influenza community. There is no doubt that an improved influenza vaccine is on the horizon.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30617121      PMCID： PMC6327971          DOI： 10.4049/jimmunol.1801054

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


  110 in total

1.  Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines.

Authors:  Xiao-Song He; Tyson H Holmes; Caiqiu Zhang; Kutubuddin Mahmood; George W Kemble; David B Lewis; Cornelia L Dekker; Harry B Greenberg; Ann M Arvin
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

2.  Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus.

Authors:  Timothy J Powell; Tara Strutt; Joyce Reome; Joseph A Hollenbaugh; Alan D Roberts; David L Woodland; Susan L Swain; Richard W Dutton
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

Review 3.  Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults.

Authors:  Manon M J Cox; Ruvim Izikson; Penny Post; Lisa Dunkle
Journal:  Ther Adv Vaccines       Date:  2015-07

4.  A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.

Authors:  Emily J Erbelding; Diane J Post; Erik J Stemmy; Paul C Roberts; Alison Deckhut Augustine; Stacy Ferguson; Catharine I Paules; Barney S Graham; Anthony S Fauci
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

5.  An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera.

Authors:  Laura Couzens; Jin Gao; Kim Westgeest; Matthew Sandbulte; Vladimir Lugovtsev; Ron Fouchier; Maryna Eichelberger
Journal:  J Virol Methods       Date:  2014-09-16       Impact factor: 2.014

6.  Structure and mechanism of the M2 proton channel of influenza A virus.

Authors:  Jason R Schnell; James J Chou
Journal:  Nature       Date:  2008-01-31       Impact factor: 49.962

7.  Antibody response to the M2 protein of influenza A virus expressed in insect cells.

Authors:  R A Black; P A Rota; N Gorodkova; H D Klenk; A P Kendal
Journal:  J Gen Virol       Date:  1993-01       Impact factor: 3.891

8.  Prospects for universal influenza virus vaccine.

Authors:  Walter Gerhard; Krystyna Mozdzanowska; Darya Zharikova
Journal:  Emerg Infect Dis       Date:  2006-04       Impact factor: 6.883

Review 9.  Immune History and Influenza Vaccine Effectiveness.

Authors:  Joseph A Lewnard; Sarah Cobey
Journal:  Vaccines (Basel)       Date:  2018-05-21

10.  Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses.

Authors:  Danuta M Skowronski; Naveed Z Janjua; Gaston De Serres; Suzana Sabaiduc; Alireza Eshaghi; James A Dickinson; Kevin Fonseca; Anne-Luise Winter; Jonathan B Gubbay; Mel Krajden; Martin Petric; Hugues Charest; Nathalie Bastien; Trijntje L Kwindt; Salaheddin M Mahmud; Paul Van Caeseele; Yan Li
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240
View more
  26 in total

1.  Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes.

Authors:  Hsin-Yu Liao; Shih-Chi Wang; Yi-An Ko; Kuo-I Lin; Che Ma; Ting-Jen Rachel Cheng; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-15       Impact factor: 11.205

2.  Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant.

Authors:  Jan Tavernier; Sarah Gerlo; Bram Van Den Eeckhout; Lien Van Hoecke; Elianne Burg; Sandra Van Lint; Frank Peelman; Niko Kley; Gilles Uzé; Xavier Saelens
Journal:  NPJ Vaccines       Date:  2020-07-23       Impact factor: 7.344

3.  Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine.

Authors:  Kevin J Kramer; Erin M Wilfong; Kelsey Voss; Sierra M Barone; Andrea R Shiakolas; Nagarajan Raju; Caroline E Roe; Naveenchandra Suryadevara; Lauren M Walker; Steven C Wall; Ariana Paulo; Samuel Schaefer; Debolanle Dahunsi; Camille S Westlake; James E Crowe; Robert H Carnahan; Jeffrey C Rathmell; Rachel H Bonami; Ivelin S Georgiev; Jonathan M Irish
Journal:  Nat Commun       Date:  2022-06-16       Impact factor: 17.694

Review 4.  Influenza B: Prospects for the Development of Cross-Protective Vaccines.

Authors:  Liudmila M Tsybalova; Liudmila A Stepanova; Edward S Ramsay; Andrey V Vasin
Journal:  Viruses       Date:  2022-06-17       Impact factor: 5.818

5.  Adjuvant effects of killed Lactobacillus casei DK128 on enhancing T helper type 1 immune responses and the efficacy of influenza vaccination in normal and CD4-deficient mice.

Authors:  Yu-Jin Jung; Ki-Hye Kim; Eun-Ju Ko; Youri Lee; Min-Chul Kim; Young-Tae Lee; Cheol-Hyun Kim; Subbiah Jeeva; Bo Ryoung Park; Sang-Moo Kang
Journal:  Vaccine       Date:  2020-07-13       Impact factor: 3.641

6.  Tissue-resident CD4+ T helper cells assist the development of protective respiratory B and CD8+ T cell memory responses.

Authors:  Young Min Son; In Su Cheon; Yue Wu; Chaofan Li; Zheng Wang; Xiaochen Gao; Yao Chen; Yoshimasa Takahashi; Yang-Xin Fu; Alexander L Dent; Mark H Kaplan; Justin J Taylor; Weiguo Cui; Jie Sun
Journal:  Sci Immunol       Date:  2021-01-08

7.  Neuraminidase antigenic drift of H3N2 clade 3c.2a viruses alters virus replication, enzymatic activity and inhibitory antibody binding.

Authors:  Harrison Powell; Andrew Pekosz
Journal:  PLoS Pathog       Date:  2020-06-29       Impact factor: 6.823

8.  Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant.

Authors:  Jan Tavernier; Sarah Gerlo; Bram Van Den Eeckhout; Lien Van Hoecke; Elianne Burg; Sandra Van Lint; Frank Peelman; Niko Kley; Gilles Uzé; Xavier Saelens
Journal:  NPJ Vaccines       Date:  2020-07-23       Impact factor: 7.344

9.  Intranasal Nanoparticle Vaccination Elicits a Persistent, Polyfunctional CD4 T Cell Response in the Murine Lung Specific for a Highly Conserved Influenza Virus Antigen That Is Sufficient To Mediate Protection from Influenza Virus Challenge.

Authors:  Sean A Nelson; Thamotharampillai Dileepan; Amy Rasley; Marc K Jenkins; Nicholas O Fischer; Andrea J Sant
Journal:  J Virol       Date:  2021-07-26       Impact factor: 5.103

Review 10.  Targeting the Host Response: Can We Manipulate Extracellular Matrix Metalloproteinase Activity to Improve Influenza Virus Infection Outcomes?

Authors:  Jess Pedrina; John Stambas
Journal:  Front Mol Biosci       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.